Metronomic chemotherapy: new rationale for new directions

Eddy Pasquier(Children's Cancer Institute Australia), Maria Kavallaris(UNSW Sydney), Nicolás André(Hôpital d'Enfants)

Nature Reviews Clinical Oncology

June 8, 2010

10.1038/nrclinonc.2010.82

Cited by 649

Abstract

Related Papers

Tumor Angiogenesis: Therapeutic Implications

Louis M. Sherwood, Edith E. Parris, Judah Folkman|New England Journal of Medicine|1971|10.1k

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

John M.L. Ebos, Christina R. Lee, William Cruz‐Muñoz et al.|Cancer Cell|2009|1.7k

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling et al.|PubMed|2000|1.6k

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

François Ghiringhelli, Cédric Menard, Pierre E. Puig et al.|Cancer Immunology Immunotherapy|2006|1.2k

Tumor cell senescence in cancer treatment.

Igor B. Roninson|PubMed|2003|608